Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):241-242. doi: 10.1016/j.clml.2016.10.002. Epub 2017 Jan 11.

Authors

Selim Sid¹, Jerome Rey¹, Aude Charbonnier¹, Evelyne D'Incan¹, Bilal Mohty¹, Didier Blaise², Norbert Vey²

Affiliations

¹ Hematology Department, Institut Paoli-Calmettes, Marseille, France.
² Hematology Department, Institut Paoli-Calmettes, Marseille, France; Aix Marseille Université, Marseille, France.

PMID: 28196687
DOI: 10.1016/j.clml.2016.10.002

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / administration & dosage
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / pathology
Mutation*
Niacinamide / administration & dosage
Niacinamide / analogs & derivatives
Phenylurea Compounds / administration & dosage
Postoperative Care
Recurrence
Retreatment
Sorafenib
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Phenylurea Compounds
Niacinamide
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Azacitidine